A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.
Epistemonikos ID: b64865baf39ec06aba813b9f3f8ee45f097ecb9d
First added on: May 22, 2017